Immunocore Holdings PLC (NAS:IMCR)
$ 46.05 -1.93 (-4.02%) Market Cap: 2.30 Bil Enterprise Value: 1.85 Bil PE Ratio: 0 PB Ratio: 5.07 GF Score: 73/100

Immunocore Holdings PLC at Citi Virtual Oncology Leadership Summit Transcript

Feb 22, 2023 / 05:00PM GMT
Release Date Price: $57.61 (-1.69%)
Andrew Simon Baum;David Berman
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD;Immunocore Holdings plc - Head of

So welcome back to our next session. My name is Andrew Baum, I run Global Healthcare here at Citi. Delighted to introduce an old friend, David Berman, David is Head of R&D at Immunocore, before that at Bristol-Myers Squibb and has touched many of the approved immuno-oncology drugs on the market over the years. It's good to have you. Also joined by Clay, who runs IR at Immunocore.

Now what I was going to do is unlike some of the majors, where many of you will be very familiar with the technology in hand because Immunocore developed and markets their own lead product, KIMMTRAK, many of you may be unfamiliar with the technology. So I was just going to hand over to David just to set a common denominator and differentiate the TCR-based approach with the bispecifics, which many of you will be familiar with, which address external antigens.

So David, good to have you here, and over to you for [the scene] setting.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot